Lipella pharmaceuticals inc. LIPO.US Overview
LIPO AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
LIPO Current Performance
6.38%
Lipella pharmaceuticals inc.
-1.01%
Avg of Sector
-0.79%
S&P500
LIPO Key Information
LIPO Financial Forecast
Unit : USD
LIPO Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -1.29 | - | 34.4% | 80.38K | - | 0.5% | -687.6% |
| 2024Q1 | -0.96 | - | 0% | 136.43M | - | 0.3% | -817% |
| 2023Q4 | -1.28 | - | 0% | 145.88K | - | -0.1% | -570.1% |
LIPO Profile
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Price of LIPO
LIPO FAQ
When is LIPO's latest earnings report released?
The most recent financial report for Lipella pharmaceuticals inc. (LIPO) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating LIPO’s short-term business performance and financial health. For the latest updates on LIPO’s earnings releases, visit this page regularly.
What is the operating profit of LIPO?
According to the latest financial report, Lipella pharmaceuticals inc. (LIPO) reported an Operating Profit of -1.33M with an Operating Margin of -1,026.22% this period, representing a decline of 9.05% compared to the same period last year. Operating Profit reflects the company’s core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is LIPO's revenue growth?
In the latest financial report, Lipella pharmaceuticals inc. (LIPO) announced revenue of 129.39K, with a Year-Over-Year growth rate of -11.3%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does LIPO have?
At the end of the period, Lipella pharmaceuticals inc. (LIPO) held Total Cash and Cash Equivalents of 4.23M, accounting for 0.87 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does LIPO go with three margins increasing?
In the latest report, Lipella pharmaceuticals inc. (LIPO) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -1,026.22%%, and net margin of -1,009.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess LIPO’s profit trajectory and future growth potential.
Is LIPO's EPS continuing to grow?
According to the past four quarterly reports, Lipella pharmaceuticals inc. (LIPO)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.64. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of LIPO?
Lipella pharmaceuticals inc. (LIPO)’s Free Cash Flow (FCF) for the period is -1.43M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 2.71% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.